Kura Oncology to Participate in Three Upcoming Investor Conferences
February 09 2017 - 04:05PM
Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage
biopharmaceutical company, today announced that Troy Wilson, Ph.D.,
J.D., President and Chief Executive Officer, is scheduled to
present an overview of the company at three upcoming investor
conferences.
- Leerink Partners 6th Annual Global Healthcare Conference, New
York, February 16, 2017 at 9:30 a.m. EST (6:30 a.m. PST)
- Cowen and Company 37th Annual Healthcare Conference, Boston,
March 8, 2017 at 9:20 a.m. EST (6:20 a.m. PST)
- Oppenheimer 27th Annual Healthcare Conference, New York, March
21, 2017 at 1:35 p.m. EDT (10:35 a.m. PDT)
A live audio webcast and replay of each presentation will be
available in the Investors section of Kura Oncology's website at
www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura Oncology’s lead drug candidate is
tipifarnib, a farnesyl transferase inhibitor, which is currently
being studied in multiple Phase 2 clinical trials. The pipeline
includes KO-947, an ERK inhibitor, and KO-539, an inhibitor of the
menin-MLL protein-protein interactions. For additional information
about Kura Oncology, please visit the company’s website at
www.kuraoncology.com.
CONTACT INFORMATION
INVESTOR CONTACT:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
CORPORATE COMMUNICATIONS CONTACT:
Mark Corbae
Vice President
Canale Communications
(619) 849-5375
mark@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2023 to Mar 2024